Literature DB >> 24493102

Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models.

Ludivine Fronton1, Sabine Pilari, Wilhelm Huisinga.   

Abstract

The structure, interpretation and parameterization of classical compartment models as well as physiologically-based pharmacokinetic (PBPK) models for monoclonal antibody (mAb) disposition are very diverse, with no apparent consensus. In addition, there is a remarkable discrepancy between the simplicity of experimental plasma and tissue profiles and the complexity of published PBPK models. We present a simplified PBPK model based on an extravasation rate-limited tissue model with elimination potentially occurring from various tissues and plasma. Based on model reduction (lumping), we derive several classical compartment model structures that are consistent with the simplified PBPK model and experimental data. We show that a common interpretation of classical two-compartment models for mAb disposition-identifying the central compartment with the total plasma volume and the peripheral compartment with the interstitial space (or part of it)-is not consistent with current knowledge. Results are illustrated for the monoclonal antibodies 7E3 and T84.66 in mice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24493102     DOI: 10.1007/s10928-014-9349-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  40 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

2.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

3.  Serum immunoglobulin levels in healthy children and adults.

Authors:  J W Stoop; B J Zegers; P C Sander; R E Ballieux
Journal:  Clin Exp Immunol       Date:  1969-01       Impact factor: 4.330

4.  Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.

Authors:  Nathanael L Dirks; Arno Nolting; Andreas Kovar; Bernd Meibohm
Journal:  J Clin Pharmacol       Date:  2008-01-24       Impact factor: 3.126

5.  Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice.

Authors:  H A El-Masri; C J Portier
Journal:  Drug Metab Dispos       Date:  1998-06       Impact factor: 3.922

6.  Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  MAbs       Date:  2013-02-13       Impact factor: 5.857

7.  Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice.

Authors:  V Ghetie; J G Hubbard; J K Kim; M F Tsen; Y Lee; E S Ward
Journal:  Eur J Immunol       Date:  1996-03       Impact factor: 5.532

8.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

9.  Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.

Authors:  W Huisinga; A Solms; L Fronton; S Pilari
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

Review 10.  Pharmacokinetic models for FcRn-mediated IgG disposition.

Authors:  Jim J Xiao
Journal:  J Biomed Biotechnol       Date:  2012-05-14
View more
  23 in total

1.  MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.

Authors:  Silvia Maria Lavezzi; Enrica Mezzalana; Stefano Zamuner; Giuseppe De Nicolao; Peiming Ma; Monica Simeoni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-11-10       Impact factor: 2.745

2.  Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.

Authors:  Miro J Eigenmann; Tine V Karlsen; Ben-Fillippo Krippendorff; Olav Tenstad; Ludivine Fronton; Michael B Otteneder; Helge Wiig
Journal:  J Physiol       Date:  2017-10-29       Impact factor: 5.182

3.  Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.

Authors:  Wolfgang F Richter; Gregory J Christianson; Nicolas Frances; Hans Peter Grimm; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2018-05-09       Impact factor: 5.857

Review 4.  Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.

Authors:  David Ternant; Nicolas Azzopardi; William Raoul; Theodora Bejan-Angoulvant; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.

Authors:  David Ternant; Theodora Bejan-Angoulvant; Christophe Passot; Denis Mulleman; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

6.  Impact of altered endogenous IgG on unspecific mAb clearance.

Authors:  Saskia Fuhrmann; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-24       Impact factor: 2.745

7.  Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.

Authors:  Linzhong Li; Iain Gardner; Miroslav Dostalek; Masoud Jamei
Journal:  AAPS J       Date:  2014-07-09       Impact factor: 4.009

8.  Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.

Authors:  Cornelius Cilliers; Hans Guo; Jianshan Liao; Nikolas Christodolu; Greg M Thurber
Journal:  AAPS J       Date:  2016-06-10       Impact factor: 4.009

Review 9.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.

Authors:  Tian Yu; Elena Y Enioutina; Hermine I Brunner; Alexander A Vinks; Catherine M Sherwin
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.